Triple

T1169412
Position Surface form Disambiguated ID Type / Status
Subject Spinraza E24879 entity
Predicate modifiesGeneExpression P14972 FINISHED
Object SMN2
SMN2 is a human gene that produces a backup form of survival motor neuron protein and is a key therapeutic target in spinal muscular atrophy.
E135135 NE FINISHED

How this triple was built (5 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: SMN2 | Statement: [Spinraza, modifiesGeneExpression, SMN2]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: SMN2
Context triple: [Spinraza, modifiesGeneExpression, SMN2]
  • A. SOD1
    SOD1 is a gene encoding the antioxidant enzyme superoxide dismutase 1, whose mutations are a major known cause of familial amyotrophic lateral sclerosis (ALS).
  • B. C9orf72
    C9orf72 is a human gene whose hexanucleotide repeat expansions are the most common known genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
  • C. survival motor neuron protein
    Survival motor neuron protein is an essential cellular protein required for the maintenance and function of motor neurons, whose deficiency leads to spinal muscular atrophy.
  • D. spinal muscular atrophy
    Spinal muscular atrophy is a genetic neuromuscular disorder characterized by progressive muscle weakness and atrophy due to degeneration of motor neurons in the spinal cord.
  • E. Spinraza
    Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: SMN2
Triple: [Spinraza, modifiesGeneExpression, SMN2]
Generated description
SMN2 is a human gene that produces a backup form of survival motor neuron protein and is a key therapeutic target in spinal muscular atrophy.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: SMN2
Target entity description: SMN2 is a human gene that produces a backup form of survival motor neuron protein and is a key therapeutic target in spinal muscular atrophy.
  • A. SOD1
    SOD1 is a gene encoding the antioxidant enzyme superoxide dismutase 1, whose mutations are a major known cause of familial amyotrophic lateral sclerosis (ALS).
  • B. C9orf72
    C9orf72 is a human gene whose hexanucleotide repeat expansions are the most common known genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
  • C. survival motor neuron protein
    Survival motor neuron protein is an essential cellular protein required for the maintenance and function of motor neurons, whose deficiency leads to spinal muscular atrophy.
  • D. spinal muscular atrophy
    Spinal muscular atrophy is a genetic neuromuscular disorder characterized by progressive muscle weakness and atrophy due to degeneration of motor neurons in the spinal cord.
  • E. Spinraza
    Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
  • F. None of above. chosen
PD Predicate disambiguation gpt-5-mini-2025-08-07
Target predicate: modifiesGeneExpression
Context triple: [Spinraza, modifiesGeneExpression, SMN2]
  • A. leafModification
    Indicates a relationship where an entity undergoes or causes a change in the structure, form, or characteristics of a leaf.
  • B. geneticInfluence
    Indicates that one entity affects or contributes to the genetic traits, characteristics, or heredity of another entity.
  • C. regulatoryInteraction chosen
    Indicates a relationship where one entity modulates, controls, or influences the activity, expression, or function of another entity through regulatory mechanisms.
  • D. isFrequentlyAdapted
    Indicates that a work or source material is often transformed or re-created into new formats or versions, such as films, plays, or other media.
  • E. mayBeModifiedBy
    Indicates that an entity has the potential to be altered, changed, or updated by another entity or process.
  • F. None of above.

Provenance (6 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a494082a7c819095004f423f294a64 completed March 1, 2026, 7:31 p.m.
NER Named-entity recognition batch_69a4bce821b481908bc278a3fa7973f4 completed March 1, 2026, 10:25 p.m.
NED1 Entity disambiguation (via context triple) batch_69ac6f17aa608190920b7df62b8dd903 completed March 7, 2026, 6:31 p.m.
NEDg Description generation batch_69ac6fc5442c8190a5d824881f05d468 completed March 7, 2026, 6:34 p.m.
NED2 Entity disambiguation (via description) batch_69ac7026dda48190a72f671dba9ac17b completed March 7, 2026, 6:36 p.m.
PD Predicate disambiguation batch_69a4bb5656948190b0b1d5446ad06005 completed March 1, 2026, 10:19 p.m.
Created at: March 1, 2026, 7:45 p.m.